{"nctId":"NCT00797511","briefTitle":"Immunogenicity and Safety of Adacel Polio Vaccine","startDateStruct":{"date":"2008-11"},"conditions":["Diphtheria","Tetanus","Pertussis","Poliomyelitis"],"count":132,"armGroups":[{"label":"Study Group","type":"EXPERIMENTAL","interventionNames":["Biological: TdcP-IPV vaccine"]}],"interventions":[{"name":"TdcP-IPV vaccine","otherNames":["ADACEL POLIO"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 6 to 8 years on the day of inclusion\n* Informed consent form signed by the parent(s) or another legally acceptable representative\n* Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures\n* Written documentation of complete primary series and fourth dose of diphtheria, tetanus, pertussis (DTP) and Polio vaccines\n* Parent(s)/legal representative present or fully completed pre-inclusion medical questionnaire.\n\nExclusion Criteria:\n\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy\n* Known systemic hypersensitivity to any of the vaccine components (or residues carried over from manufacture, such as formaldehyde, glutaraldehyde, streptomycin, neomycin and polymyxin B ) or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances with specific focus on subjects who had, after previous administration of DTP vaccine, one of the pre-listed adverse events.\n* Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator\n* Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy\n* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response\n* Receipt of any vaccine in the 4 weeks preceding the trial vaccination\n* Planned receipt of any vaccine in the 4 weeks following the trial vaccination\n* Known Human Immunodeficiency Virus (HIV), Hepatitis B surface (HBs) antigen, or Hepatitis C seropositivity\n* History of diphtheria and/or tetanus and/or pertussis and/or poliomyelitis infection (confirmed either clinically, serologically or microbiologically)\n* Previous fifth vaccination against diphtheria and/or tetanus and/or pertussis and/or poliomyelitis diseases with either the trial vaccine or another vaccine\n* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular (IM) vaccination\n* Subject at high risk for diphtheria and/or tetanus and/or pertussis and/or poliomyelitis infection during the trial\n* Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw\n* Febrile illness (temperature ≥ 37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Years","maximumAge":"8 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Seroprotection to Vaccine Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine.","description":"Diphtheria concentrations determined by diphtheria toxin neutralization assay (Dip SN); Tetanus concentrations determined by enzyme-linked immunosorbent assay (ELISA).\n\nSeroprotection titer levels were defined as: Anti-diphtheria antibody titers ≥0.1 international unit (IU) per milliliter (mL); Anti-tetanus antibody titers ≥0.01 IU/mL and ≥0.1 IU/mL; Anti-Polio (≥ 8 1/dilution).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Booster Response to Vaccine Pertussis Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine.","description":"The anti-Pertussis concentration were determined by ELISA. The criteria for demonstrating booster response are: (i) Pre-vaccination antibody concentrations less than the lower limit of quantitation (LLOQ) for each anti-pertussis antibody (PT, FHA, FIM, and PRN) but a post-vaccination levels ≥ 4 x LLOQ; or (ii) Pre-vaccination antibody concentrations ≥ LLOQ but \\< 4 x LLOQ with a 4-fold rise rate; or (iii) Pre-vaccination antibody concentrations ≥ 4 x LLOQ but with a 2-fold rise rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Antibodies to ADACEL Polio Vaccine Antigens Following Vaccination","description":"Diphtheria antibody concentrations determined by diphtheria toxin neutralization assay; Tetanus antibody concentrations determined by enzyme-linked immunosorbent assay (ELISA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9627","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7083","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9860","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers of Antibodies to Pertussis Antigens Following Vaccination With ADACEL Polio","description":"Pre- and post-vaccination GMTs for the Pertussis toxoid (PT), Pertussis filamentous hemagglutinin (FHA), Pertussis pertactin (PRN), and Pertussis Fimbriae types 2 and 3 (FIM), all determined by enzyme-linked immunosorbent assay (ELISA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"423","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"314","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting at Least 1 Solicited Injection Site or Systemic Reaction Post-vaccination With ADACEL Polio Vaccine","description":"Solicited Injection Site Reactions: Pain, Erythema/redness, Swelling, and Extensive swelling of vaccinated limb. Solicited Systemic Reactions: Fever (temperature ≥ 37.5ºC), Headache, Malaise, and Myalgia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":132},"commonTop":["Injection Site Pain","Injection site Erythema","Myalgia","Injection Site Swelling","Headache"]}}}